Market Research Logo

Gastric Cancer - Pipeline Review, H1 2018

Gastric Cancer - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Pipeline Review, H1 2018, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.

Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 14, 80, 99, 11, 97, 17 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 9, 3, 1, 9 and 2 molecules, respectively.

Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Gastric Cancer - Overview
Gastric Cancer - Therapeutics Development
Gastric Cancer - Therapeutics Assessment
Gastric Cancer - Companies Involved in Therapeutics Development
Gastric Cancer - Drug Profiles
Gastric Cancer - Dormant Projects
Gastric Cancer - Discontinued Products
Gastric Cancer - Product Development Milestones
Appendix
List of Tables
Table 1: Number of Products under Development for Gastric Cancer, H1 2018 43
Table 2: Number of Products under Development by Companies, H1 2018 45
Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018 46
Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018 47
Table 5: Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018 48
Table 6: Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018 49
Table 7: Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018 50
Table 8: Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018 51
Table 9: Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018 52
Table 10: Number of Products under Development by Companies, H1 2018 (Contd..8), H1 2018 53
Table 11: Number of Products under Development by Companies, H1 2018 (Contd..9), H1 2018 54
Table 12: Number of Products under Development by Companies, H1 2018 (Contd..10), H1 2018 55
Table 13: Number of Products under Development by Universities/Institutes, H1 2018 56
Table 14: Products under Development by Companies, H1 2018 58
Table 15: Products under Development by Companies, H1 2018 (Contd..1), H1 2018 59
Table 16: Products under Development by Companies, H1 2018 (Contd..2), H1 2018 60
Table 17: Products under Development by Companies, H1 2018 (Contd..3), H1 2018 61
Table 18: Products under Development by Companies, H1 2018 (Contd..4), H1 2018 62
Table 19: Products under Development by Companies, H1 2018 (Contd..5), H1 2018 63
Table 20: Products under Development by Companies, H1 2018 (Contd..6), H1 2018 64
Table 21: Products under Development by Companies, H1 2018 (Contd..7), H1 2018 65
Table 22: Products under Development by Companies, H1 2018 (Contd..8), H1 2018 66
Table 23: Products under Development by Companies, H1 2018 (Contd..9), H1 2018 67
Table 24: Products under Development by Companies, H1 2018 (Contd..10), H1 2018 68
Table 25: Products under Development by Companies, H1 2018 (Contd..11), H1 2018 69
Table 26: Products under Development by Companies, H1 2018 (Contd..12), H1 2018 70
Table 27: Products under Development by Companies, H1 2018 (Contd..13), H1 2018 71
Table 28: Products under Development by Companies, H1 2018 (Contd..14), H1 2018 72
Table 29: Products under Development by Companies, H1 2018 (Contd..15), H1 2018 73
Table 30: Products under Development by Companies, H1 2018 (Contd..16), H1 2018 74
Table 31: Products under Development by Companies, H1 2018 (Contd..17), H1 2018 75
Table 32: Products under Development by Companies, H1 2018 (Contd..18), H1 2018 76
Table 33: Products under Development by Universities/Institutes, H1 2018 77
Table 34: Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018 78
Table 35: Number of Products by Stage and Target, H1 2018 80
Table 36: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018 81
Table 37: Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018 82
Table 38: Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018 83
Table 39: Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018 84
Table 40: Number of Products by Stage and Target, H1 2018 (Contd..5), H1 2018 85
Table 41: Number of Products by Stage and Target, H1 2018 (Contd..6), H1 2018 86
Table 42: Number of Products by Stage and Mechanism of Action, H1 2018 88
Table 43: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018 89
Table 44: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018 90
Table 45: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018 91
Table 46: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018 92
Table 47: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..5), H1 2018 93
Table 48: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..6), H1 2018 94
Table 49: Number of Products by Stage and Route of Administration, H1 2018 96
Table 50: Number of Products by Stage and Molecule Type, H1 2018 98
Table 51: Gastric Cancer - Pipeline by 3SBio Inc, H1 2018 99
Table 52: Gastric Cancer - Pipeline by AbbVie Inc, H1 2018 100
Table 53: Gastric Cancer - Pipeline by AbGenomics International Inc, H1 2018 100
Table 54: Gastric Cancer - Pipeline by Abion Inc, H1 2018 100
Table 55: Gastric Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2018 101
Table 56: Gastric Cancer - Pipeline by ADC Therapeutics SA, H1 2018 101
Table 57: Gastric Cancer - Pipeline by Advenchen Laboratories LLC, H1 2018 102
Table 58: Gastric Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H1 2018 102
Table 59: Gastric Cancer - Pipeline by Alteogen Inc, H1 2018 102
Table 60: Gastric Cancer - Pipeline by Ambrx Inc, H1 2018 103
Table 61: Gastric Cancer - Pipeline by amcure GmbH, H1 2018 103
Table 62: Gastric Cancer - Pipeline by Amgen Inc, H1 2018 104
Table 63: Gastric Cancer - Pipeline by ANP Technologies Inc, H1 2018 104
Table 64: Gastric Cancer - Pipeline by Antikor Biopharma Ltd, H1 2018 104
Table 65: Gastric Cancer - Pipeline by arGEN-X BV, H1 2018 105
Table 66: Gastric Cancer - Pipeline by Array BioPharma Inc, H1 2018 105
Table 67: Gastric Cancer - Pipeline by Asana BioSciences LLC, H1 2018 106
Table 68: Gastric Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018 106
Table 69: Gastric Cancer - Pipeline by Astellas Pharma Inc, H1 2018 107
Table 70: Gastric Cancer - Pipeline by AstraZeneca Plc, H1 2018 107
Table 71: Gastric Cancer - Pipeline by Atara Biotherapeutics Inc, H1 2018 108
Table 72: Gastric Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H1 2018 108
Table 73: Gastric Cancer - Pipeline by Avipep Pty Ltd, H1 2018 108
Table 74: Gastric Cancer - Pipeline by Basilea Pharmaceutica Ltd, H1 2018 109
List of Figures
Figure 1: Number of Products under Development for Gastric Cancer, H1 2018 43
Figure 2: Number of Products under Development by Companies, H1 2018 44
Figure 3: Number of Products under Development by Universities/Institutes, H1 2018 56
Figure 4: Number of Products by Top 10 Targets, H1 2018 79
Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018 79
Figure 6: Number of Products by Top 10 Mechanism of Actions, H1 2018 87
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018 87
Figure 8: Number of Products by Top 10 Routes of Administration, H1 2018 95
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H1 2018 95
Figure 10: Number of Products by Top 10 Molecule Types, H1 2018 97
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1 2018 97

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report